TECHNOLOGY LICENSING OPPORTUNITY: DC Recruiter

Scope

DC Recruiter: Broad-Spectrum Immune Enhancer from scientists at Los Alamos National Laboratory offers a differentiated approach to multi-pathogen infection prevention by using a self-assembling peptide nanofiber to recruit and activate dendritic cells (DCs), the immune system’s natural sentinels.

Unlike pathogen-specific vaccines or therapeutics, it is designed to help trigger an early immune response regardless of the infecting agent.

Its needle-free, spray-friendly concept adds practicality.

The Challenge: DC Recruiter addresses a persistent and highly consequential gap in infection management: the need for a rapid, broadly effective way to stimulate immune defense before the specific pathogen is known.

In many exposure scenarios, the body encounters a threat before clinicians can identify the cause, and that delay can reduce the effectiveness of conventional interventions.

Current vaccines, antibiotics and antivirals are generally designed to act against a known target, which limits their usefulness when exposure is unexpected, diagnosis is delayed or the pathogen is unfamiliar.

That limitation creates a clear unmet need for a fast-acting, broad-spectrum approach that can be deployed early, with minimal complexity, and in settings where rapid response matters most, including outbreak situations, field environments and other high-risk conditions.

Problems Solved: DC Recruiter solves this problem by using a specific peptide selected to bind to dendritic cells.

By leveraging a self-assembling peptide nanofiber platform, the technology is designed to help “wake up” immune surveillance early, before infection can progress unchecked.

Rather than relying on a treatment matched to one virus or bacterium, it creates the potential for broad-spectrum immune support across many different...